Objectives: Ceftobiprole is a novel broad-spectrum cephalosporin with good in vitro activity against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. The objective of this study was to assess the in vivo activity of ceftobiprole against four strains of E. faecalis, including b-lactamaseproducing (Bla1) and vancomycin-resistant strains.
Introduction
The current clinical challenges posed by enterococci include the increased incidence of nosocomial infections and the lack of enterococcal activity of several compounds due either to intrinsic resistance or the acquisition of resistance genes. Moreover, although still rare, resistance to recently approved antimicrobial agents with anti-enterococcal activity (e.g. daptomycin) 1 -4 has been documented in Enterococcus faecalis and other enterococcal species indicating that new therapeutic options for enterococcal infections might be needed in the future.
Ceftobiprole is a novel broad-spectrum, b-lactamase-stable, parenteral cephalosporin with high affinity for the penicillin binding proteins (PBPs) of Gram-positive cocci, 5 including PBP2a of Staphylococcus aureus and PBP2x of pneumococci. 6 The in vitro activity of ceftobiprole includes b-lactamase-producing and vancomycin-resistant E. faecalis 7 and ampicillin-susceptible Enterococcus faecium. 5, 8 Ceftobiprole medocaril (formerly BAL5788) is a water-soluble prodrug that has been used previously in several animal models including a mouse model of sepsis for Gram-positive and Gram-negative bacteria, 5 a mouse abscess model of methicillin-resistant S. aureus (MRSA) and S. aureus with intermediate resistance to vancomycin (VISA) 9 and a mouse pneumonia model with Haemophilus influenzae, Enterobacter cloacae and Klebsiella pneumoniae. 10 Rat and rabbit models 11, 12 of MRSA and VISA endocarditis have also evaluated the activity of ceftobiprole medocaril in these infections. The tissue cage model (which is a foreign body infection model in which bacteria are injected into pre-implanted Teflon tissue cages) 9 has also been established to assess the activity of ceftobiprole against MRSA. In general, ceftobiprole has comparable or superior activity versus the comparators (vancomycin, linezolid or other b-lactams) in all models with a good correlation between in vitro susceptibility and in vivo activity. Clinical data on complicated skin and soft tissue infections indicated that ceftobiprole was as effective and safe as vancomycin in treating patients with these conditions. 13 Phase III clinical trials of ceftobiprole medocaril in the treatment of hospital-and community-acquired pneumonia are currently underway.
14 The mouse peritonitis model has been extensively used in the past to evaluate the in vivo antibiotic activity against enterococci but its use to assess the activity of ceftobiprole against E. faecalis isolates has not been reported. Although ceftobiprole has shown good in vitro activity against E. faecalis, 7 in vivo data are lacking. Moreover, its in vitro spectrum indicates that it would be active against b-lactamase producers and vancomycin-resistant isolates of E. faecalis.
7 Therefore, our main goal was to evaluate the in vivo activity of ceftobiprole medocaril against isolates of E. faecalis, including ones exhibiting either vancomycin resistance or production of b-lactamase, in the mouse peritonitis model. We also sought to determine if the presence of b-lactamase in E. faecalis produced an in vivo effect in this model, despite the in vitro susceptibility at the standard inoculum for laboratory testing.
Materials and methods

Bacterial isolates
Four well characterized isolates of E. faecalis were included in this study (Table 1) : (i) HH22 (TX0921), a Houston isolate from 1981, which was the first enterococcal isolate found to produce b-lactamase; 15 (ii) TX2484, also recovered in Houston in 1994 from the blood of a patient and harbouring the vanB gene cluster; 16 (iii) V583, a vancomycin-resistant isolate (whose genome has been sequenced) recovered from the bloodstream of a patient; 17, 18 and (iv) OG1RF, a laboratory strain of E. faecalis that exhibits rifampicin and fusidic acid resistance 19 used extensively for evaluation of E. faecalis.
20,21
Antibiotics and in vitro susceptibility testing 22 E. faecalis ATCC 29212 and S. aureus ATCC 29213 strains were included as controls. High inoculum MICs in broth (using 10 7 cfu/mL) of ampicillin and ceftobiprole were determined for isolate E. faecalis HH22 in cation-adjusted MH broth (Becton -Dickinson and Company) following the recommendations of the CLSI.
22
Mouse peritonitis model
Female, 4-to 6-week-old, outbred ICR mice (Harlan SpragueDawley, Houston) weighing between 19.1 and 25 g were used as described previously. 23 Each dosing group was composed of six animals. Bacteria for inoculation were grown on brain heart infusion (BHI) agar (Difco Laboratories, Detroit, MI, USA) and subsequently inoculated in BHI broth at 378C for 24 h. Mice were injected intraperitoneally with 1 mL of a solution containing the E. faecalis strain in 12.5% suspended sterile rat faecal extract 23 with an inoculum of !10Â the LD 50 (LD 50 s of HH22, OG1RF and V583 were previously described; 24 for isolate TX2484, LD 50 was determined before the therapeutic assay). Antibiotics (ceftobiprole medocaril and ampicillin dissolved in water) were given subcutaneously as a single dose. Ampicillin doses of 100, 50, 25, 12.5 and 6.25 mg/kg were administered. For ceftobiprole, doses of 25, 12.5, 6.25, 3.12 and 1.56 mg/kg were used. To compensate for differences in halflife between ceftobiprole and ampicillin, an additional experiment was performed administering a second dose of ampicillin subcutaneously to animals infected with strain HH22 (TX0921), 2 h after 23 mice were monitored every 24 h for 96 h. The LD 50 and 50% protective dose (PD 50 ) were determined by the method described by Reed and Muench. 25 All animal experiments followed the pre-approved guidelines of the Animal Welfare Committee of the University of Texas Health Science Center at Houston. Comparison of the survival curves of the ceftobiprole-and ampicillin-treated groups at similar doses was performed using a log-rank test with Prism for Windows w (version 4.00 GraphPad Software). A value of P , 0.05 was considered significant.
Results and discussion
In vitro activity of ceftobiprole
All four E. faecalis isolates had ceftobiprole MICs ,0.5 mg/L, whereas vancomycin MICs were 0.5, 1, 128 and .512 mg/L for HH22, OG1RF, V583 and TX2484, respectively. Ampicillin MICs at standard inoculum were 1 mg/L for all four isolates. Use of a high inoculum increased the ampicillin MIC for isolate HH22 to 512 mg/L but produced only a minor rise in the ceftobiprole MIC (from 0.5 to 1 mg/L). These results confirmed the stability of ceftobiprole against b-lactamase-producing enterococci and its good in vitro activity against the vancomycinresistant E. faecalis isolates.
In vivo activity of ceftobiprole against b-lactamase-producing E. faecalis Figure 1 shows the dose -response curves for the b-lactamaseproducing E. faecalis HH22 (Figure 1a ) and the laboratory strain OG1RF (Figure 1b) . Ampicillin did not protect mice against intraperitoneal challenge with E. faecalis HH22 (inoculum of 1Â10 9 cfu/mL, which was~10Â the calculated LD 50 for the strain) at the administered doses (PD 50 .100 mg/kg) ( Table 1) with lethality similar to the control group (without antibiotic) (Figure 1a) , demonstrating an in vivo effect of the b-lactamase enzyme in the peritonitis model when a high bacterial inoculum is used. In contrast, ceftobiprole medocaril protected 100% and 83.3% of mice against intraperitoneal challenge with strain HH22 at a dose of 6.25 and 3.12 mg/kg, respectively (Figure 1a) , with a PD 50 of 2 mg/kg body weight (Table 1) . In contrast, for OG1RF, both ceftobiprole and ampicillin were protective for all mice at doses of 12.5 and 25 mg/kg, respectively ( Figure 1b) (P ¼ 1.0, log-rank test) . Similarly, no difference in mouse survival was found between ceftobiprole and ampicillin at lower doses (83.3% versus 66.6% survival at 96 h at doses of 12.5 mg/kg of ampicillin versus 6.25 mg/kg of ceftobiprole, respectively; P ¼ 0.55) with a PD 50 of 4.2 and 8 mg/kg for ceftobiprole and ampicillin (single dose), respectively ( Table 1) .
We also evaluated survival of mice after peritoneal challenge with strain HH22 (b-lactamase-producing) after administering two doses of ampicillin (given subcutaneously, 2 h apart) and compared survival with that of the ceftobiprole group. We found no difference in mortality between administering one or two doses of ampicillin (PD 50 . 100 mg/kg for both groups) (Figure 1a ). These findings confirm the in vivo effect of the enterococcal b-lactamase in the peritonitis model and demonstrate the good in vivo activity of ceftobiprole against this b-lactamase-producing strain.
The enterococcal b-lactamase enzyme is identical to the class A staphylococcal enzyme 15 and ceftobiprole is a poor substrate for class A enzymes ( particularly the staphylococcal penicillinase PC1). 5 In a previous study, the rate of ceftobiprole hydrolysis of the class A staphylococcal PC1 enzyme was only 0.93 mol of substrate hydrolysed/mol of enzyme/min, whereas for penicillin it was 10 000 mol of substrate hydrolysed/mol of enzyme/min. 5 Therefore, it is likely that the activity of ceftobiprole against b-lactamase-producing E. faecalis is due to its inherent stability to hydrolysis by this enzyme. Figure 1 . Survival and dose-response curves for mice infected intraperitoneally with (a) E. faecalis HH22 (a b-lactamase producer) and (b) OG1RF. Ceftobiprole (BPR) (dotted lines) and ampicillin (AMP) (continuous lines) were given subcutaneously. All animal groups received the same dose range of antibiotics (see the Materials and methods section) and only the lowest doses of ceftobiprole or ampicillin that protected 100% of mice at 96 h are depicted (doses above the one shown had the same effect). For HH22, ampicillin was administered as a single dose (Â1) or in two doses given 2 h apart (Â2). Only single dose ampicillin is shown for OG1RF.
In vivo activity of ceftobiprole against vancomycin-resistant enterococci Figure 2 shows the dose -response curves for strains TX2484 (Figure 2a ) and V583 (Figure 2b ) (VanB vancomycin-resistant isolates) after intraperitoneal challenge with 1.7 Â 10 8 and 2.1 Â 10 9 cfu/mL, respectively ($10 Â the calculated PD 50 for the strain). Both ampicillin (25 mg/kg Â 1) and ceftobiprole (12.5 mg/kg Â 1) protected 100% of mice (P ¼ 1.0, log-rank test). The PD 50 s of ceftobiprole and ampicillin were 7.7 mg/kg and 12.5 mg/kg, respectively, for TX2484 (Table 1) , and 5.2 and 16.4 mg/kg, respectively, for V583 ( Table 1) . The results indicate that the efficacy of ceftobiprole in the mouse peritonitis model is independent of vancomycin resistance. Also, our findings support the fact that the activity of ceftobiprole is comparable to that of ampicillin in the mouse peritonitis model for non-b-lactamase-producing ampicillin-susceptible strains of E. faecalis, a unique characteristic of ceftobiprole amongst the cephalosporins.
The affinity of ceftobiprole for PBP2a of staphylococci is notable (IC 50 for competition with fluorescein-labelled ampicillin was reported to be 0.87 mM for ceftobiprole, as compared with 115 mM and .500 mM for ceftriaxone and methicillin, respectively). 5 It is plausible that members of the pyrrolidinone-3-ylidenemethyl cephems (to which ceftobiprole belongs) also exhibit high affinities for the E. faecalis PBPs and this feature may explain its in vivo and in vitro activity. As a caveat, ceftobiprole lacks affinity for PBP5 of E. faecium 5 (IC 50 . 500 mM) which is commonly overexpressed and/or mutated 26 in multiresistant isolates of E. faecium, indicating that this compound will not be useful in the treatment of resistant E. faecium infections.
In conclusion, we found an in vivo effect of the E. faecalis b-lactamase when ampicillin was used as therapy in the mouse peritonitis model that is probably related to the high inoculum used, similar in some aspects to the high density of organisms found in cardiac vegetations where the presence of this enzyme in E. faecalis also showed a biological effect when ampicillin was used, despite in vitro susceptibility at standard inoculum. 27 However, the dose -response curves and PD 50 s of ceftobiprole for HH22 and non-b-lactamase-producing isolates showed no evidence of an in vivo effect of the enterococcal b-lactamase against ceftobiprole. The in vivo data presented here support the activity of ceftobiprole against isolates of E. faecalis including vancomycin-resistant and b-lactamase-producing strains. Our findings indicate that ceftobiprole is a promising novel alternative for multidrug-resistant E. faecalis infections and support its further exploration as a therapeutic agent in humans. 
